DLL3 expression is a predictive marker of sensitivity to adjuvant chemotherapy for pulmonary LCNEC.
Adjuvant chemotherapy
delta-like 3
large cell neuroendocrine carcinoma
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
18
05
2020
revised:
23
06
2020
accepted:
26
06
2020
pubmed:
22
7
2020
medline:
16
11
2021
entrez:
22
7
2020
Statut:
ppublish
Résumé
The mammalian Notch family ligands delta-like 3 (DLL3) is reported to be a potential therapeutic target for large cell neuroendocrine carcinomas (LCNEC). The effect of DLL3 expression on LCNEC prognosis has not yet been elucidated. We reviewed the medical records of 70 LCNEC patients undergoing surgical resection between 2001 and 2015 using a prospectively maintained database. We performed immunohistochemistry for DLL3 and investigated the correlation between the sensitivity of LCNEC to platinum-based adjuvant chemotherapy. DLL3 expression was positive in 26 (37.1%) LCNEC patients. A total of 23 patients (32.9%) received platinum-based adjuvant chemotherapy. Among patients with DLL3 expression-positive tumors, no difference was found in the five-year overall survival (OS) or recurrence-free survival (RFS) between patients with and without adjuvant chemotherapy (surgery + chemotherapy vs. surgery alone, five-year OS: 58.3% vs. 35.7% P = 0.36, five-year RFS: 41.7% vs. 35.7% P = 0.74). In contrast, among patients with DLL3-negative tumors, significantly greater five-year OS and RFS rates were observed for patients with adjuvant chemotherapy than for those without it (surgery + chemotherapy vs. surgery alone: five-year OS: 90.0% vs. 26.9% P<0.01, five-year RFS: 80.0% vs. 21.7% P < 0.01). A multivariate analysis for the RFS revealed that adjuvant chemotherapy was a significant independent prognostic factor among patients with DLL3-negative tumors (hazard ratio [HR]: 0.05, 95% confidence interval [CI]: 0.01-0.41, P < 0.01), although it was not a factor among patients with DLL3-positive tumors (HR: 0.73, 95% CI: 0.23-2.27, P = 0.58). Our results revealed that DLL3 is a predictive marker of sensitivity to platinum-based adjuvant chemotherapy for LCNEC. SIGNIFICANT FINDINGS OF THE STUDY: DLL3 was a predictive marker of sensitivity to platinum-based adjuvant chemotherapy for LCNEC. Among patients with DLL3 expression-negative LCNEC, platinum-based adjuvant chemotherapy significantly improved the OS and RFS, although it did not do so among patients with DLL3 expression-positive LCNEC. Our results suggest that DLL3 expression-positive LCNEC may be better treated with other types of adjuvant chemotherapy, such as the anti-DLL3 therapies if these effects are confirmed by ongoing clinical research.
Sections du résumé
BACKGROUND
The mammalian Notch family ligands delta-like 3 (DLL3) is reported to be a potential therapeutic target for large cell neuroendocrine carcinomas (LCNEC). The effect of DLL3 expression on LCNEC prognosis has not yet been elucidated.
METHODS
We reviewed the medical records of 70 LCNEC patients undergoing surgical resection between 2001 and 2015 using a prospectively maintained database. We performed immunohistochemistry for DLL3 and investigated the correlation between the sensitivity of LCNEC to platinum-based adjuvant chemotherapy.
RESULTS
DLL3 expression was positive in 26 (37.1%) LCNEC patients. A total of 23 patients (32.9%) received platinum-based adjuvant chemotherapy. Among patients with DLL3 expression-positive tumors, no difference was found in the five-year overall survival (OS) or recurrence-free survival (RFS) between patients with and without adjuvant chemotherapy (surgery + chemotherapy vs. surgery alone, five-year OS: 58.3% vs. 35.7% P = 0.36, five-year RFS: 41.7% vs. 35.7% P = 0.74). In contrast, among patients with DLL3-negative tumors, significantly greater five-year OS and RFS rates were observed for patients with adjuvant chemotherapy than for those without it (surgery + chemotherapy vs. surgery alone: five-year OS: 90.0% vs. 26.9% P<0.01, five-year RFS: 80.0% vs. 21.7% P < 0.01). A multivariate analysis for the RFS revealed that adjuvant chemotherapy was a significant independent prognostic factor among patients with DLL3-negative tumors (hazard ratio [HR]: 0.05, 95% confidence interval [CI]: 0.01-0.41, P < 0.01), although it was not a factor among patients with DLL3-positive tumors (HR: 0.73, 95% CI: 0.23-2.27, P = 0.58).
CONCLUSIONS
Our results revealed that DLL3 is a predictive marker of sensitivity to platinum-based adjuvant chemotherapy for LCNEC.
KEY POINTS
SIGNIFICANT FINDINGS OF THE STUDY: DLL3 was a predictive marker of sensitivity to platinum-based adjuvant chemotherapy for LCNEC. Among patients with DLL3 expression-negative LCNEC, platinum-based adjuvant chemotherapy significantly improved the OS and RFS, although it did not do so among patients with DLL3 expression-positive LCNEC.
WHAT THIS STUDY ADDS
Our results suggest that DLL3 expression-positive LCNEC may be better treated with other types of adjuvant chemotherapy, such as the anti-DLL3 therapies if these effects are confirmed by ongoing clinical research.
Identifiants
pubmed: 32691982
doi: 10.1111/1759-7714.13574
pmc: PMC7471044
doi:
Substances chimiques
DLL3 protein, human
0
Intracellular Signaling Peptides and Proteins
0
Membrane Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2561-2569Informations de copyright
© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
J Thorac Dis. 2019 Apr;11(4):1145-1154
pubmed: 31179056
Cancer. 1990 Apr 15;65(8):1864-6
pubmed: 2317765
J Clin Oncol. 2006 Jan 1;24(1):70-6
pubmed: 16382115
Front Oncol. 2016 Apr 14;6:94
pubmed: 27148486
Hum Mol Genet. 2011 Mar 1;20(5):905-16
pubmed: 21147753
J Thorac Cardiovasc Surg. 2013 Mar;145(3):839-46
pubmed: 22498090
Lung Cancer. 2014 Jun;84(3):254-8
pubmed: 24679951
Clin Cancer Res. 2019 Dec 1;25(23):6958-6966
pubmed: 31506387
Ann Thorac Surg. 2006 Nov;82(5):1802-7
pubmed: 17062251
Dev Dyn. 2007 Oct;236(10):2943-51
pubmed: 17849441
Development. 1997 Aug;124(16):3065-76
pubmed: 9272948
Sci Transl Med. 2015 Aug 26;7(302):302ra136
pubmed: 26311731
J Cell Biol. 2007 Jul 30;178(3):465-76
pubmed: 17664336
Mod Pathol. 2006 Oct;19(10):1358-68
pubmed: 16862075
Anticancer Drugs. 2010 Jan;21(1):89-93
pubmed: 19770636
J Clin Oncol. 2005 Dec 1;23(34):8774-85
pubmed: 16314638
J Thorac Oncol. 2012 Jul;7(7):1179-83
pubmed: 22617247
J Thorac Oncol. 2015 Aug;10(8):1133-41
pubmed: 26039012
Nat Commun. 2018 Mar 13;9(1):1048
pubmed: 29535388
Lung Cancer. 2006 Jul;53(1):111-5
pubmed: 16697073
Nature. 2015 Aug 6;524(7563):47-53
pubmed: 26168399
Chest. 2009 Jul;136(1):260-271
pubmed: 19584208
Lung Cancer. 2019 Sep;135:73-79
pubmed: 31447005
J Thorac Oncol. 2015 Sep;10(9):1240-1242
pubmed: 26291007
J Thorac Cardiovasc Surg. 2009 Aug;138(2):446-53
pubmed: 19619794
Ann Thorac Surg. 2019 Aug;108(2):377-383
pubmed: 31004586
Diagn Pathol. 2019 May 20;14(1):47
pubmed: 31109352
Lancet Oncol. 2017 Jan;18(1):42-51
pubmed: 27932068
Gen Thorac Cardiovasc Surg. 2014 Jun;62(6):351-6
pubmed: 24719260